AXSM
Price
$118.31
Change
+$0.12 (+0.10%)
Updated
Sep 24, 11:43 AM (EDT)
Capitalization
5.9B
47 days until earnings call
MMIRF
Price
$0.09
Change
+$0.04 (+80.00%)
Updated
Sep 16 closing price
Capitalization
40.73M
Interact to see
Advertisement

AXSM vs MMIRF

Header iconAXSM vs MMIRF Comparison
Open Charts AXSM vs MMIRFBanner chart's image
Axsome Therapeutics
Price$118.31
Change+$0.12 (+0.10%)
Volume$300
Capitalization5.9B
Medmira
Price$0.09
Change+$0.04 (+80.00%)
Volume$500
Capitalization40.73M
AXSM vs MMIRF Comparison Chart in %
Loading...
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AXSM vs. MMIRF commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXSM is a Hold and MMIRF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (AXSM: $118.19 vs. MMIRF: $0.09)
Brand notoriety: AXSM and MMIRF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AXSM: 73% vs. MMIRF: 6%
Market capitalization -- AXSM: $5.9B vs. MMIRF: $40.73M
AXSM [@Biotechnology] is valued at $5.9B. MMIRF’s [@Biotechnology] market capitalization is $40.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXSM’s FA Score shows that 0 FA rating(s) are green whileMMIRF’s FA Score has 0 green FA rating(s).

  • AXSM’s FA Score: 0 green, 5 red.
  • MMIRF’s FA Score: 0 green, 5 red.
According to our system of comparison, MMIRF is a better buy in the long-term than AXSM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXSM’s TA Score shows that 5 TA indicator(s) are bullish while MMIRF’s TA Score has 4 bullish TA indicator(s).

  • AXSM’s TA Score: 5 bullish, 4 bearish.
  • MMIRF’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, AXSM is a better buy in the short-term than MMIRF.

Price Growth

AXSM (@Biotechnology) experienced а +3.58% price change this week, while MMIRF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.31%. For the same industry, the average monthly price growth was +10.09%, and the average quarterly price growth was +53.86%.

Reported Earning Dates

AXSM is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+4.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AXSM($5.9B) has a higher market cap than MMIRF($40.7M). MMIRF YTD gains are higher at: 587.023 vs. AXSM (39.688). MMIRF has higher annual earnings (EBITDA): -3.24M vs. AXSM (-230.81M). AXSM has more cash in the bank: 303M vs. MMIRF (18.3K). MMIRF has less debt than AXSM: MMIRF (10.2M) vs AXSM (217M). AXSM has higher revenues than MMIRF: AXSM (495M) vs MMIRF (254K).
AXSMMMIRFAXSM / MMIRF
Capitalization5.9B40.7M14,491%
EBITDA-230.81M-3.24M7,133%
Gain YTD39.688587.0237%
P/E RatioN/AN/A-
Revenue495M254K194,882%
Total Cash303M18.3K1,655,738%
Total Debt217M10.2M2,127%
FUNDAMENTALS RATINGS
AXSM vs MMIRF: Fundamental Ratings
AXSM
MMIRF
OUTLOOK RATING
1..100
7796
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
36
Fair valued
PROFIT vs RISK RATING
1..100
62100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5234
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MMIRF's Valuation (36) in the null industry is somewhat better than the same rating for AXSM (90) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew somewhat faster than AXSM’s over the last 12 months.

AXSM's Profit vs Risk Rating (62) in the Pharmaceuticals Other industry is somewhat better than the same rating for MMIRF (100) in the null industry. This means that AXSM’s stock grew somewhat faster than MMIRF’s over the last 12 months.

AXSM's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as MMIRF (100) in the null industry. This means that AXSM’s stock grew similarly to MMIRF’s over the last 12 months.

MMIRF's Price Growth Rating (34) in the null industry is in the same range as AXSM (52) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew similarly to AXSM’s over the last 12 months.

MMIRF's P/E Growth Rating (100) in the null industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that MMIRF’s stock grew similarly to AXSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXSMMMIRF
RSI
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
70%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
64%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
70%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
61%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
N/A
Declines
ODDS (%)
Bearish Trend 9 days ago
81%
N/A
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
71%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MMIRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VCRCX14.570.10
+0.69%
NYLI CBRE Global Infrastructure Class C
ICRNX10.140.05
+0.50%
VY® CBRE Global Real Estate A
RWMAX65.93-0.01
-0.02%
American Funds Washington Mutual R1
HRSRX85.90-0.21
-0.24%
Hood River Small-Cap Growth Investor
CFSLX11.81-0.03
-0.25%
Column Small Cap

AXSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXSM has been loosely correlated with PLRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AXSM jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXSM
1D Price
Change %
AXSM100%
+0.60%
PLRX - AXSM
39%
Loosely correlated
-2.67%
CRNX - AXSM
38%
Loosely correlated
+6.35%
ALNY - AXSM
38%
Loosely correlated
-0.98%
XENE - AXSM
36%
Loosely correlated
-0.11%
FULC - AXSM
35%
Loosely correlated
-1.34%
More

MMIRF and

Correlation & Price change

A.I.dvisor tells us that MMIRF and SGMT have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MMIRF and SGMT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MMIRF
1D Price
Change %
MMIRF100%
N/A
SGMT - MMIRF
32%
Poorly correlated
-1.17%
NWPHF - MMIRF
29%
Poorly correlated
N/A
VTYX - MMIRF
26%
Poorly correlated
-1.06%
AXSM - MMIRF
21%
Poorly correlated
+0.60%
DNTH - MMIRF
21%
Poorly correlated
+0.29%
More